(Updated - April 13, 2026 2:39 PM EDT)

Leerink Partners analyst Thomas Smith raised the price target on Syre ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments

Spyre (SYRE) PT Raised to $85 at JefferiesApril 13, 2026 12:37 PM Spyre (SYRE) PT Raised to $98 at BTIGApril 13, 2026 11:24 AM Spyre (SYRE) PT Raised to $80 at WedbushApril 13, 2026 10:38 AM Stifel on Spyre (SYRE): 'solid foundation for combos where we expect synergistic activity'April 13, 2026 8:45 AM Goldman Sachs on Spyre (SYRE): 'Initial SPY001 efficacy data bolsters confidence into remaining data readouts later this year'April 13, 2026 8:26 AM Leerink on Spyre (SYRE): 'one of our Top Picks for 2026'April 13, 2026 8:21 AM TD Cowen on Spyre (SYRE): 'we expect these data to further raise the ceiling for Spyre's future combos'April 13, 2026 7:57 AM Mizuho on Spyre (SYRE): 'We see these results as an extremely favorable outcome'April 13, 2026 7:54 AM Form 8-K Spyre Therapeutics, Inc. For: Apr 13April 13, 2026 7:47 AM Guggenheim on Top Pick Spyre (SYRE): 'We expect the stock could be up >40% on today's news'April 13, 2026 7:46 AM Spyre reports positive trial results for ulcerative colitis drug SPY001April 13, 2026 7:00 AM Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsApril 13, 2026 7:00 AM Spyre Therapeutics (SYRE) Halted, News PendingApril 13, 2026 6:56 AM Form ARS Spyre Therapeutics, Inc. For: Dec 31April 10, 2026 4:14 PM Form DEFA14A Spyre Therapeutics, Inc. April 10, 2026 4:05 PM Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026April 10, 2026 4:05 PM Form DEF 14A Spyre Therapeutics, Inc. For: May 27April 10, 2026 4:02 PM